Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab) for Metastatic NSCLC

Shots:

• The company has completed the enrolment in the P-III CONTACT-01 trial evaluating cabozantinib + atezolizumab in a ratio (1:1) in 366 patients with metastatic NSCLC prior treated with an immune checkpoint inhibitor & Pt-containing CT. The study is sponsored by Roche & co-funded by Exelixis
• The 1EPs of a trial are OS & 2EPs include PFS, ORR & DoR. The study has built from cohort 7 of the P-Ib COSMIC-021 trial results
• Cabometyx has received the US FDA’s approval for advanced RCC, HCC, advanced RCC, thyroid cancer & has also received regulatory approvals in the EU & other countries. Zymeworks holds the exclusive rights to develop & commercialize cabozantinib in the US

Click here to­ read the full press release/ article | Ref: Businesswire | Image: Exelixis